Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).

Trial Profile

Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Irritable bowel syndrome
  • Focus Biomarker; Therapeutic Use
  • Acronyms MIBS
  • Most Recent Events

    • 30 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 21 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 06 Jun 2013 Accrual to date is 125% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top